Literature DB >> 17212613

Selegiline and blood pressure in patients with Parkinson's disease.

V Pursiainen1, T J Korpelainen, H T Haapaniemi, A K Sotaniemi, V V Myllylä.   

Abstract

OBJECTIVES: Parkinson's disease (PD) frequently affects both the extrapyramidal system and the autonomic nervous system (ANS), the latter also being sometimes disturbed by PD medications. Specifically selegiline is known to disturb cardiovascular ANS functions and may cause or enhance orthostatic hypotension.
METHODS: In order to study the effect of the withdrawal of selegiline on the regulation of blood pressure (BP) in advanced PD, an orthostatic test was performed in 14 PD patients with wearing-off before the morning levodopa dose and thereafter repetitively at 1-h intervals for up to 4 h. A Unified Parkinson's Disease Rating Scale motor score evaluation was also carried out hourly. The tests were repeated after a 4-week selegiline washout period.
RESULTS: Selegiline withdrawal decreased systolic BP significantly during the on-stage in a supine position as well as during the orthostatic test. The initial drop of BP in the orthostatic test was significantly smaller after selegiline withdrawal. The heart rate remained unaffected.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17212613     DOI: 10.1111/j.1600-0404.2006.00742.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

Review 1.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

2.  Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review.

Authors:  Takashi Tsuboi; Yuki Satake; Keita Hiraga; Katsunori Yokoi; Makoto Hattori; Masashi Suzuki; Kazuhiro Hara; Adolfo Ramirez-Zamora; Michael S Okun; Masahisa Katsuno
Journal:  NPJ Parkinsons Dis       Date:  2022-06-13

3.  Feasibility of clinical hypnosis for the treatment of Parkinson's disease: a case study.

Authors:  Gary Elkins; Jim Sliwinski; Juliette Bowers; Elmyra Encarnacion
Journal:  Int J Clin Exp Hypn       Date:  2013

Review 4.  Orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism.

Authors:  Seyed-Mohammad Fereshtehnejad; Johan Lökk
Journal:  Parkinsons Dis       Date:  2014-02-02

Review 5.  Parkinson's disease between internal medicine and neurology.

Authors:  Ilona Csoti; Wolfgang H Jost; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-23       Impact factor: 3.575

Review 6.  Cardiovascular/Stroke Risk Stratification in Parkinson's Disease Patients Using Atherosclerosis Pathway and Artificial Intelligence Paradigm: A Systematic Review.

Authors:  Jasjit S Suri; Sudip Paul; Maheshrao A Maindarkar; Anudeep Puvvula; Sanjay Saxena; Luca Saba; Monika Turk; John R Laird; Narendra N Khanna; Klaudija Viskovic; Inder M Singh; Mannudeep Kalra; Padukode R Krishnan; Amer Johri; Kosmas I Paraskevas
Journal:  Metabolites       Date:  2022-03-31

7.  Effect of Acute Levodopa Up-Titration on Blood Pressure in Patients With Early Stage Parkinson's Disease: Results of a Levodopa Challenge Test.

Authors:  Xiaoqin He; Chengjun Mo; Yi Zhang; Ying Cai; Xiaodong Yang; Yiwei Qian; Qin Xiao
Journal:  Front Aging Neurosci       Date:  2022-01-03       Impact factor: 5.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.